Cargando…

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection

Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive and fatal disease with a median survival of 36 months. With the advent of genetic sequencing to identify individual genomic profiles and acquired tumor-specific pathways, targeted therapies have revolutionized cancer treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales:	LeVee, Alexis, Lin, Ching Ying, Posadas, Edwin, Figlin, Robert, Bhowmick, Neil A, Di Vizio, Dolores, Ellis, Leigh, Rosser, Charlos J, Freeman, Michael R, Theodorescu, Dan, Freedland, Stephen J, Gong, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450162/ https://www.ncbi.nlm.nih.gov/pubmed/34552338 http://dx.doi.org/10.2147/OTT.S315170

Ejemplares similares

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
por: Uche, An, et al.
Publicado: (2019)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

The Challenges of Treating Patients with Breast Cancer and Obesity
por: LeVee, Alexis, et al.
Publicado: (2023)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

1444. Urine Screening Prior to Surgical Valve Replacement: Should It Be Performed?
por: LeVee, Alexis, et al.
Publicado: (2019)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]
Publicado: (2021)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

Eosinophilic pneumonia: A rare manifestation of amiodarone toxicity diagnosed using traditional bronchoscopy
por: LeVee, Alexis, et al.
Publicado: (2019)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
por: Karzai, Fatima, et al.
Publicado: (2018)

Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States
por: Xu, Chenxia, et al.
Publicado: (2022)

Dubin-Johnson Syndrome Presenting During Cardiac Transplantation Evaluation
por: LeVee, Alexis, et al.
Publicado: (2020)

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib
por: Gong, Lifeng, et al.
Publicado: (2022)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
por: Kim, Joseph W., et al.
Publicado: (2023)

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

Large oncosomes mediate intercellular transfer of functional microRNA
por: Morello, Matteo, et al.
Publicado: (2013)

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
por: Sekine, Mana, et al.
Publicado: (2023)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
por: Carr, T. Hedley, et al.
Publicado: (2021)

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
por: Matsubara, Nobuaki, et al.
Publicado: (2023)

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials
por: Luo, Zhanyang, et al.
Publicado: (2023)

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study
por: Juan Fita, María José, et al.
Publicado: (2023)

Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study
por: Johnston, Ashley W., et al.
Publicado: (2020)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
por: Freedland, Stephen J., et al.
Publicado: (2021)

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
por: Freedland, Stephen J., et al.
Publicado: (2023)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
por: Mateo, Joaquin, et al.
Publicado: (2020)

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
por: Pan, Jian, et al.
Publicado: (2022)

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
por: Ryan, Charles J., et al.
Publicado: (2021)

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer
por: Moreira, Daniel M., et al.
Publicado: (2015)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_or8qvklnb105ltij82lt9fdqcl